SCHEMBL2985665

SCHEMBL2985665

NS(=O)(=O)c1nn2c(-c3ccc(C(F)(F)F)cc3)cnc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.46
DYRK2 Q92630 2/20 0.46
PTGS2 P35354 3/20 0.44
CYP2C9 P11712 1/20 0.44
PDPK1 O15530 1/20 0.44
DYRK3 O43781 1/20 0.43
CCNA2 P20248 1/20 0.43
CDK2 P24941 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
KIF11 P52732 3/20 0.43
CHRNA7 P36544 2/20 0.40
PIK3CA P42336 4/20 0.39
PTGS1 P23219 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981234 0.99 KIF11 (0.46) DYRK1ADYRK2PTGS2CYP2C9PDPK1
SCHEMBL2984298 0.90 PDPK1 (0.41) DYRK1ADYRK2PTGS2CYP2C9PDPK1
SCHEMBL2981781 0.87 DYRK1A (0.46) DYRK1ADYRK2PTGS2PDPK1DYRK3
SCHEMBL2983635 0.87 CA12 (0.41) DYRK1ADYRK2PTGS2CYP2C9CCNA2
SCHEMBL2985796 0.87 CA1 (0.43) PDPK1CA12CA1CA2CA9
SCHEMBL2983702 0.85 CA12 (0.48) PTGS2PTGS1CA12CA1CA2
SCHEMBL3537637 0.84 PIK3CA (0.41) DYRK1APTGS2CDK2PIK3CAPTGS1
SCHEMBL2970467 0.84 CA1 (0.42) PTGS2CDK2PTGS1CA12CA1
SCHEMBL2979751 0.84 FYN (0.50) CA12CA1CA2CA9CA3
SCHEMBL2979908 0.83 PIK3CA (0.42) PIK3CACA1CA2CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772260-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-08-10 US disclosed
US-7741349-B2 Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-06-22 US disclosed
US-7714003-B2 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-05-11 US disclosed
US-7700635-B2 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS INC. (CA) 2010-04-20 US disclosed
EP-1463735-B1 IMIDAZO¬2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES AEGERA THERAPEUTICS INC (CA) 2009-08-12 EP disclosed
US-20090042953-A1 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES AEGERA THERAPEUTICS, INC. (CA) 2009-02-12 US disclosed
US-20070265319-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-11-15 US disclosed
US-20070238766-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-10-11 US disclosed
US-20070238768-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-10-11 US disclosed
US-7230019-B2 Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-06-12 US disclosed
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-04-19 US disclosed
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides AEGERA THERAPEUTICS, INC. (CA) 2007-01-25 US disclosed
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides PHARMASCIENCE INC. (CA) 2007-01-25 US disclosed
US-20050069492-A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides PHARMASCIENCE INC. (CA) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021476-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885
US-20090042953-A1 IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES PMP22, SMN1; SMN2, BDNF DYRK1A 3634/4885DYRK2 3128/4885PTGS2 323/4885
US-20070265319-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885
US-20070238766-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885
US-20070238768-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885
US-20070021416-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885
US-20070088059-A1 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides SMN1; SMN2, PMP22, BDNF DYRK1A 4068/4885DYRK2 3565/4885PTGS2 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.